SINGAPORE PLANT
November 1st, 2002
BY MARK ROWEUS pharmaceutical giant Schering-Plough has opened (NOTE: LAST WEEK) two drug manufacturing plants in Singapore worth Sing$320 million (Euro 231 million). A sterile facility with investments worth Sing$180 (Euro122 million) will be used for the freeze-drying, finishing and packaging of leading drugs for the treatment of hepatitis C and Crohn's disease, which causes inflammation of the intestines. Another Sing$140 (Euro 109 million) facility will manufacture Zetia tablets, a new drug for cholesterol management. Schering-Plough also plans to build a new ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.